121 related articles for article (PubMed ID: 2408446)
1. Platelet responses observed during and after infusions of the prostacyclin analog ZK 36 374.
Yardumian DA; Mackie IJ; Bull H; Machin SJ
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():359-62. PubMed ID: 2408446
[No Abstract] [Full Text] [Related]
2. Iloprost in peripheral vascular disease--platelet function and clinical outcome.
Fitscha P; Tiso B; Sinzinger H
Prog Clin Biol Res; 1987; 242():463-8. PubMed ID: 2444993
[No Abstract] [Full Text] [Related]
3. Control of human and animal platelet aggregation by a new prostacyclin analog.
Maderna P; Colli S; Sirtori C; Tremoli E; Paoletti R
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():363-9. PubMed ID: 2408447
[TBL] [Abstract][Full Text] [Related]
4. The novel effect of a new prostacyclin analogue ZK36374 on the aggregation of human platelets in whole blood.
Saniabadi AR; Lowe GD; Belch JJ; Forbes CD; Prentice CR; Barbenel JC
Thromb Haemost; 1983 Oct; 50(3):718-21. PubMed ID: 6196854
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of ciloprost (ZK 36 374): a chemically stable and biologically potent prostacyclin analog.
Skuballa W; Vorbrüggen H
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():299-305. PubMed ID: 6189381
[No Abstract] [Full Text] [Related]
6. Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog, in severe peripheral arterial disease (PAD).
Oberender H; Krais T; Schäfer M; Belcher G
Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():311-6. PubMed ID: 2473610
[No Abstract] [Full Text] [Related]
7. Temporary inhibition of platelet function with iloprost (ZK36374) preserves canine platelets during extracorporeal membrane oxygenation.
Cottrell ED; Kappa JR; Stenach N; Fisher CA; Tuszynski GP; Switalska HI; Addonizio VP
J Thorac Cardiovasc Surg; 1988 Oct; 96(4):535-41. PubMed ID: 2459560
[TBL] [Abstract][Full Text] [Related]
8. Platelet function studies during and after infusions of ZK 36374, a stable prostacyclin analogue, to healthy volunteers.
Yardumian DA; Mackie IJ; Brennan EC; Bull H; Machin SJ
Haemostasis; 1986; 16(1):20-6. PubMed ID: 2422095
[TBL] [Abstract][Full Text] [Related]
9. Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behaviour in man.
Cowley AJ; Heptinstall S; Hampton JR
Thromb Haemost; 1985 Feb; 53(1):90-4. PubMed ID: 2581332
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibition of the platelet activation sequence: shape change, micro- and macro-aggregation, by a stable prostacyclin analogue (Iloprost).
Pedvis LG; Wong T; Frojmovic MM
Thromb Haemost; 1988 Apr; 59(2):323-8. PubMed ID: 2455359
[TBL] [Abstract][Full Text] [Related]
11. [Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study].
Diehm C; Abri O; Baitsch G; Bechara G; Beck K; Breddin HK; Brock FE; Clevert HD; Corovic D; Marshall M
Dtsch Med Wochenschr; 1989 May; 114(20):783-8. PubMed ID: 2470569
[TBL] [Abstract][Full Text] [Related]
12. Influence on platelet activity and red cell fluidity of epoprostenol and two stable prostacyclin analogues in vitro.
Maurin N
Arzneimittelforschung; 1986 Aug; 36(8):1180-3. PubMed ID: 3096342
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of the effects of taprostene (CG 4203) in patients with advanced peripheral arterial disease.
Darius H; Kopp H; Mulfinger A; Spielberger M; Todt M; Schuster CJ; Meyer J
Prog Clin Biol Res; 1989; 301():417-21. PubMed ID: 2508112
[No Abstract] [Full Text] [Related]
14. Comparison of the thromboxane synthetase inhibitor dazoxiben and the prostacyclin mimetic iloprost in an animal model of acute ischaemia and reperfusion.
Thiemermann C; Schrör K
Biomed Biochim Acta; 1984; 43(8-9):S151-4. PubMed ID: 6083783
[TBL] [Abstract][Full Text] [Related]
15. Proceedings: Refractoriness in blood platelets: effect of prior exposure to aggregating agents on subsequent aggregation responses.
Evans RJ; Gordon JL
Br J Pharmacol; 1974 May; 51(1):123P. PubMed ID: 4441772
[No Abstract] [Full Text] [Related]
16. Differential inhibition of prostacyclin production and platelet aggregation by aspirin in humans.
Masotti G; Galanti G; Poggesi L; Abbate R; Neri Serneri GG
Adv Prostaglandin Thromboxane Res; 1980; 6():317-20. PubMed ID: 6992529
[No Abstract] [Full Text] [Related]
17. Prostacyclin in vascular pathology--therapeutic possibilities.
Gryglewski RJ; Szczeklik A
Ann Clin Res; 1984; 16(5-6):253-61. PubMed ID: 6398663
[No Abstract] [Full Text] [Related]
18. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation.
Siess W; Roth P; Weber PC
Thromb Haemost; 1981 Jun; 45(3):204-7. PubMed ID: 7025338
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study.
Darius H; Hossmann V; Schrör K
Klin Wochenschr; 1986 Jun; 64(12):545-51. PubMed ID: 2426514
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide and prostacyclin modulate the alterations in cardiac action potential duration mediated by platelets during ischaemia.
Goulielmos NV; Enayat ZE; Sheridan DJ; Cohen H; Flores NA
Cardiovasc Res; 1995 Nov; 30(5):788-98. PubMed ID: 8595628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
